The primary function of the Protocol Review and Monitoring System is to ensure that all human subjects research is of the highest scientific merit and proceeds at an optimal pace. Over the past 5 years, 934 faculty members participating in human subjects research utilized the PRMS, and 273 new interventional protocols were reviewed by the PRMS in the last year. The PRMS is supported by 32 staff members under the direction of Dr. Aman Buzdar, Vice President for Clinical Research Administration. The core function of the PRMS is to provide a mechanism to ensure adequate internal oversight of the scientific and research aspects of all institutional clinical trials through a rigorous review of the scientific merit, progress, and priorities of the clinical research protocols conducted by the faculty. This function is coordinated by the PRMS as a single source of service, support and oversight The PRMS is made up of several subcommittees (described below) that are designated to provide scientific review and approval for new research protocols, as well as to monitor the progress of the ongoing trials. Importantly, the increasingly complex regulatory requirements and oversight activities have resulted in increased institutional staffing commitments and prompted provision of several new or expanded services, as described in greater detail in this application. During the last grant year, the funds used to support the PRMS function were $240,152 (8%) from the Cancer Center Support Grant (CCSG), $110,000 (4%) from IRB fees, and $2,540,868 (88%) from the institution. It is projected that in the next award cycle, the funds used to support the PRMS function will be $249,758 provided by the CCSG (9%), $110,000 from IRB fees (4%), and $2,406,755 (87%) from the institution. The PRMS consists of four Clinical Research Committees (CRCs) and one Psychosocial Behavioral Health Services Research Committee (PBHSRC) that review protocols for scientific merit. The Chairs of these committees are also members of the Electronic Protocol Accrual Auditing Committee (ePAAC) that selects and monitors all institutional protocols that are identified as slow-accruing. Eight hundred and one protocols were reviewed by ePAAC in the last fiscal year, and 115 (14%) were closed or withdrawn. During the last 6 months, substantive changes have been made 1) to make the initial review and prioritization of protocols by the CRC and the disease site programs and departments more rigorous, 2) to reduce the time required for review, and 3) to scrutinize accrual more carefully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759806
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$333,737
Indirect Cost
$125,239
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141
Fountzilas, Elena; Said, Rabih; Tsimberidou, Apostolia M (2018) Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opin Investig Drugs 27:155-162
Blanchard, Pierre; Davis, John W; Frank, Steven J et al. (2018) Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121:540-548
Niknam, Sharareh; Barsoumian, Hampartsoum B; Schoenhals, Jonathan E et al. (2018) Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res 24:5735-5743
Kamal, Mona; Ng, Sweet Ping; Eraj, Salman A et al. (2018) Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol 79:1-8
Housten, Ashley J; Pappadis, Monique R; Krishnan, Shilpa et al. (2018) Resistance to discontinuing breast cancer screening in older women: A qualitative study. Psychooncology 27:1635-1641
Hsu, Jung-Mao; Xia, Weiya; Hsu, Yi-Hsin et al. (2018) STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun 9:1908
Akay, Catherine L; Albarracin, Constance; Torstenson, Tiffany et al. (2018) Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J 24:28-34
Khong, Hiep; Volmari, Annika; Sharma, Meenu et al. (2018) Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol 200:3464-3474

Showing the most recent 10 out of 12418 publications